Education
About Us
Working with TipRanks
Follow Us
10x Genomics Inc (TXG)
NASDAQ:TXG
TXG Stock Chart & Stats
Day’s Range― - ―
52-Week Range$9.27 - $38.49
Previous CloseN/A
Volume385.49K
Average Volume (3M)3.47M
Market Cap
$1.27B
Enterprise Value$2.41B
Total Cash (Recent Filing)$65.08M
Total Debt (Recent Filing)$29.68M
Price to Earnings (P/E)―
Beta1.72
Next Earnings
Apr 30, 2025EPS Estimate
-0.46Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.52
Shares Outstanding108,245,010
10 Day Avg. Volume2,920,261
30 Day Avg. Volume3,474,040
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.08
Price to Cash Flow (P/CF)-47.10
P/FCF Ratio0.00
Enterprise Value/Market Cap1.90
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit5.82
Enterprise Value/Ebitda-18.42
Forecast
1Y Price Target
$16.36Price Target Upside57.46% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering12
---
10x Genomics News
---
Bulls Say, Bears Say
Bulls Say
Market OpportunitiesTXG's portfolio is differentiated and positions the company well for long-term opportunities in the spatial and single-cell markets.
Product InnovationTXG announced new plate workflows to increase throughput on Chromium X and iX instruments, allowing for up to 700+ samples per run and offering flexibility in workflow design.
Revenue GrowthRevenues beat expectations with a 9% increase, indicating strong performance.
Bears Say
Competitive PressureThe ongoing reorganization of TXG's sales force coincides with the introduction of lower-priced competition, adding further challenges.
Funding ChallengesTXG's business has significant exposure to the academic end-market, especially in the U.S., which poses a risk due to recent funding cuts.
Regulatory ImpactThe recently implemented NIH indirect costs cap is impacting researchers' behavior, leading to reduced spending on instruments.
---
Ownership Overview
2.14% Insiders
24.90% Mutual Funds
38.35% Other Institutional Investors
9.74% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
TXG FAQ
What was 10x Genomics Inc’s price range in the past 12 months?
10x Genomics Inc lowest stock price was $9.27 and its highest was $38.49 in the past 12 months.
What is 10x Genomics Inc’s market cap?
10x Genomics Inc’s market cap is $1.27B.
When is 10x Genomics Inc’s upcoming earnings report date?
10x Genomics Inc’s upcoming earnings report date is Apr 30, 2025 which is in 36 days.
How were 10x Genomics Inc’s earnings last quarter?
10x Genomics Inc released its earnings results on Feb 12, 2025. The company reported -$0.4 earnings per share for the quarter, missing the consensus estimate of -$0.299 by -$0.101.
Is 10x Genomics Inc overvalued?
According to Wall Street analysts 10x Genomics Inc’s price is currently Undervalued.
Does 10x Genomics Inc pay dividends?
10x Genomics Inc does not currently pay dividends.
What is 10x Genomics Inc’s EPS estimate?
10x Genomics Inc’s EPS estimate is -0.46.
How many shares outstanding does 10x Genomics Inc have?
10x Genomics Inc has 108,245,010 shares outstanding.
What happened to 10x Genomics Inc’s price movement after its last earnings report?
10x Genomics Inc reported an EPS of -$0.4 in its last earnings report, missing expectations of -$0.299. Following the earnings report the stock price went down -0.5%.
Which hedge fund is a major shareholder of 10x Genomics Inc?
Currently, no hedge funds are holding shares in TXG
---
10x Genomics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$16.36 (57.46% Upside)
$16.36 (57.46% Upside)
Blogger Sentiment
Bearish
TXG Sentiment 67%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 4.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $338.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 6.5%
Last 30 Days ▼ 6.5%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-72.65%
12-Months-Change
Fundamentals
Return on Equity
-25.17%
Trailing 12-Months
Asset Growth
-4.82%
Trailing 12-Months
Company Description
10x Genomics Inc
10x Genomics, Inc. is a biotechnology company that specializes in designing and manufacturing advanced genetic sequencing technologies. Founded in 2012 and headquartered in Pleasanton, California, the company operates in the life sciences sector, providing innovative tools for biological research. Their core products include the Chromium System, Visium Spatial Solutions, and associated software, which together allow researchers to analyze complex biological systems by providing high-resolution insights into single-cell and spatial genomics.
---
TXG Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
While the company experienced significant product innovation and customer adoption, challenges such as revenue decline, market uncertainties, and reduced funding from key stakeholders like NIH have created a cautious outlook. The highlights are balanced by substantial lowlights, leading to an overall neutral sentiment.Read More>---
TXG Revenue Breakdown
60.32% Americas
22.99% EMEA
8.45% Asia-Pacific excluding China
8.24% China
---
TXG Stock 12 Month Forecast
Average Price Target
$16.36
▲(57.46% Upside)
Technical Analysis
Illumina
―
Pacific Biosciences
―
Crispr Therapeutics AG
―
Guardant Health
―
Twist Bioscience
―
Best Analysts Covering TXG
1 Year
1 Year Success Rate
6/16 ratings generated profit
1 Year Average Return
-17.79%
reiterated a buy rating last month
Copying Tejas Savant's trades and holding each position for 1 Year would result in 37.50% of your transactions generating a profit, with an average return of -17.79% per trade.
---